AN2 Therapeutics (ANTX) Stock: Buy, Sell, or Hold?
ANTX - AN2 Therapeutics, Inc. Common Stock
$5.71
0.09 (1.60%)
â˛
5d:
+17.01%
30d:
-4.03%
90d:
+29.48%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When ANTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ANTX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ANTX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ANTX is currently trading at $5.71, which is considered slightly high relative to its 30-day fair value range of $5.05 to $5.78.
Technical Outlook: Technically, ANTX is in a uptrend. Immediate support is located at $4.67, while resistance sits at $5.99.
Market Sentiment: ANTX scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $9.00 (+60.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ANTX is in a uptrend. Immediate support is located at $4.67, while resistance sits at $5.99.
Market Sentiment: ANTX scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $9.00 (+60.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$5.05 -
$5.78
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
42.1%
All Signals
- BEARISH: Weak technical setup (38/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 60.1% below Wall St target ($9.00)
- WARNING: Composite score 51/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.05 -
$5.78
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$4.67
Resistance Level
$5.99
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.02
Wall Street Target
$9.00
(+60.1%)
Share & Embed Analysis
Last updated: October 02, 2026 4:58 PM ET
Data refreshes hourly during market hours. Next update: 5:58 PM
Data refreshes hourly during market hours. Next update: 5:58 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ANTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$92 | 46 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 65 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 76 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 42 HOLD |
